Prosorba column


Also found in: Wikipedia.

Prosorba® column

Therapeutics A blood-filtration device used during apheresis–eg, for treating ITP; it may improve severe rheumatoid arthritis in Pts who failed or are intolerant to disease-modifying antirheumatic drugs–DMARDs. See Apheresis.
References in periodicals archive ?
Fresenius HemoCare Acquires PROSORBA Column from Cypress
All of the company's revenue during 2002 is related to an agreement with Fresenius, whereby the company licensed to Fresenius rights with respect to the PROSORBA column, a medical device.
All of the Company's revenue during 2002, which was recognized during the first quarter, is related to an agreement with Fresenius, whereby the Company licensed to Fresenius rights with respect to the PROSORBA column, a medical device.
From March 1999 through January 31, 2002, all revenue was recognized pursuant to the terms of our agreement with Fresenius, whereby the Company licensed to Fresenius rights with respect to the PROSORBA column.
The FDA Advisory Panel voted 10-to-1 to recommend approval of CYPB's Prosorba Column for the treatment of rheumatoid arthritis ("RA").
From March 1999 through January 31, 2002, all of our revenue was recognized pursuant to the terms of our agreement with Fresenius, pursuant to which we licensed to Fresenius rights with respect to the PROSORBA column.
Baxter will also assume responsibility for sales promotion and marketing support for the PROSORBA column saving IMRE $1.
Baxter has recently notified the Company that in view of its existing inventories of the PROSORBA column, it will not require any shipments for the quarter ended March 31, 1995.
The company also announced today that in February 2002, the agreement with Fresenius HemoCare related to the PROSORBA column was further modified to extend the license fee period to seven years and fix the future licensing fees based on sales during the licensing fee period.
By removing antibodies that cause rejection of the transplanted heart, the PROSORBA column reversed AVR in all three patients.
We are satisfied with the progress being made by Baxter to launch the PROSORBA column," stated Martin D.